Neonc Technologies Holdings, INC 8-K filings

NeOnc Technologies Holdings, Inc. announced a scheduled End-of-Phase 1 meeting with the FDA on November 17, 2026, to discuss the development of its CNS cancer therapy, NEO212.

NeOnc Technologies Holdings, Inc. has redeemed all outstanding shares of its Series A Convertible Preferred Stock for cash, simplifying its capital structure and eliminating potential dilution.

NeOnc Technologies Holdings, Inc. reports significant open-market stock purchases by its CEO and Chief Medical Officer following positive Phase 2a results for its NEO100 therapy.

NeOnc Technologies Holdings, Inc. announced the pricing of a registered direct offering of common stock and warrants, raising approximately $15 million.

NeOnc Technologies Holdings, Inc. files an amendment to its Form 8-K to detail Nasim Shomali's appointment to the Audit Committee.

NeOnc Technologies Holdings, Inc. reported the outcomes of its 2026 annual meeting of stockholders, including the election of directors and ratification of its independent auditor.

NeOnc Technologies announced positive top-line results from the Phase 2a portion of its NEO100-01 clinical trial for recurrent IDH1 mutant high-grade glioma, demonstrating a significant improvement in overall survival.

NeOnc Technologies announced positive topline results from the Phase 2a portion of its NEO100-01 study, showing a significant improvement in progression-free survival for patients with recurrent IDH1-mutant glioma.

NeOnc Technologies reported Q2 2026 financial results, confirmed topline data for its Phase 2a NEO100 study to be presented August 12, 2026, and announced international IND approvals.

NeOnc Technologies Holdings, Inc. announced it received written feedback from the FDA regarding the CMC development program for its NEO212 drug candidate, including requirements for a capsule-to-tablet formulation transition.

NeOnc Technologies Holdings, Inc. reports the resignation of a Class II director and the immediate appointment of a new director with extensive strategy and technology experience.

NeOnc Technologies Holdings, Inc. has entered into a securities purchase agreement to raise up to $5 million through the issuance of Series A Convertible Preferred Stock.

NeOnc Technologies Holdings, Inc. announced first quarter 2026 financial results, highlighting progress in its Phase 2 CNS cancer programs, a PIPE financing, and leadership appointments.

NeOnc Technologies Holdings, Inc. has entered into a fourth securities purchase agreement to raise approximately $2 million to fund preclinical trials.

CEO Amir Heshmatpour purchased $300,000 in company stock as NeOnc prepares for key clinical data readouts and FDA meetings.

NeOnc Technologies Holdings, Inc. has entered into an Equity Distribution Agreement to sell up to $75 million of its common stock through an at-the-market offering.

NeOnc Technologies Holdings, Inc. completed an initial closing of its third Securities Purchase Agreement, raising $1 million through the issuance of common stock and warrants.

NeOnc Technologies announced positive dose-escalation results for its oral NEO212 therapy, establishing the Recommended Phase 2 Dose and showing early signs of clinical efficacy in CNS cancers.

NeOnc Technologies Holdings, Inc. announced the full settlement of a legal dispute with Fox Infused, LLC, involving a payment of $737,920.77.

NeOnc Technologies Holdings, Inc. announced the closing of an initial tranche of a new securities purchase agreement, raising $1.45 million for working capital.

NeOnc Technologies Holdings, Inc. announced an investor conference call on March 4, 2026, to present initial Phase 1 dose-escalation data for its NEO212-01 clinical trial.

NeOnc Technologies Holdings, Inc. announced an initial closing of a private placement, raising $10 million through the sale of common stock and warrants to an institutional investor.

NeOnc Technologies announced updated clinical results for intranasal NEO100, showing significant long-term survival and radiographic remission in recurrent IDH1-mutant astrocytoma patients.

NeOnc Technologies Holdings, Inc. announced a $1 million private placement of common stock and positive preclinical findings for its NEO100 therapeutic in combination with ultrasound for brain tumors.

NeOnc Technologies Holdings reports strong third-quarter 2025 financial results, significant clinical trial progress for its CNS cancer therapies, and strategic partnerships.

NeOnc Technologies announced updated Phase 1/2a clinical results for intranasal NEO100, showing significant radiographic response and long-term survival in recurrent IDH1-mutant astrocytoma patients.

NeOnc Technologies Holdings, Inc. announced an investor conference call to present updated clinical trial data for its NEO100 therapeutic.

NeOnc Technologies Holdings, Inc. announced the appointment of Amir Heshmatpour as its new CEO, with founder Dr. Thomas Chen transitioning to Chief Medical and Scientific Officer.

His Highness Sheikh Nahyan bin Zayed Al Nahyan will assume the Executive Chairmanship of NeOnc's Middle East subsidiary, NuroMENA, signaling a major strategic alliance for brain cancer treatment.

NeOnc Technologies announced the closing of its $50 million strategic partnership with Quazar Investment is set for October 23, 2025, following final UAE regulatory approvals.